跳至主要内容
临床试验/NCT02516579
NCT02516579已完成不适用

ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea

Theravia60 个研究点 分布在 3 个国家目标入组 1,906 人开始时间: 2009年1月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Theravia
入组人数
1,906
试验地点
60
主要终点
% of Patient-years With Malignancies

研究概览

简要总结

In the context of the Risk Management Plan (RMP), as requested from Addmedica by the EMEA, to collect information about long-term safety of Siklos® (hydroxycarbamide) when used in patients with Sickle Cell Disease.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female ambulatory patients, aged 2 years and more (children, adolescents or adults)
  • With symptomatic sickle cell syndrome
  • Treated with Siklos®
  • Having been informed of the study by the initiating physician and consenting to participate to the cohort.

排除标准

  • 未提供

结局指标

主要结局

% of Patient-years With Malignancies

时间窗: During the follow-up of participant, up to 10 years

% of Patient-years With Skin Ulcerations

时间窗: During the follow-up of participant, up to 10 years

Patients with at least one skin ulceration

% of Patient-years With Myelosuppressions

时间窗: During the follow-up of participant, up to 10 years

Patients with at least one myelosuppression

次要结局

未报告次要终点

研究者

发起方
Theravia
申办方类型
Industry
责任方
Sponsor

研究点 (60)

Loading locations...

相似试验